Glaukos Submits New Drug Application to U.S. FDA for Epioxa™ - Yahoo Finance

Glaukos submitted an NDA to the FDA for Epioxa, a non-invasive corneal cross-linking therapy for keratoconus, aiming to reduce procedure times, improve comfort, and shorten recovery. The submission includes data from two successful Phase 3 trials.


Related News

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™ - Yahoo Finance

Glaukos submitted an NDA to the FDA for Epioxa, a non-invasive corneal cross-linking therapy for keratoconus, aiming to reduce procedure times, improve comfort, and shorten recovery. The submission includes data from two successful Phase 3 trials.

© Copyright 2024. All Rights Reserved by MedPath